Market access update
Pricing and reimbursement of CAR‐T in Germany
CAR-T therapy: the future begins to take shape
High expectations have been built up around the pricing, reimbursement, and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies based on the novel mechanism of action and trial results that indicate curative potential for a large segment of the treatable population. However, CAR-T represents an entirely new way of delivering cancer therapy, with significant challenges for manufacturers and healthcare systems.
This eBook provides:
- overviews of pricing and reimbursement of CAR‐T in France, Germany, and the UK
- a summary of five key issues that are emerging from early regulatory, pricing, and reimbursement decisions
- five strategies for success that manufacturers could consider.